← Eichor
Condition: Refractory Thyroid Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Thyroid Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT05733013XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 · 2 location(s) · Jochen Lorch · NCT06959641Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT03099356I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
Phase N/A · 1 location(s) · Miami Cancer Research Center, Inc. · NCT06443866Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT05668962Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359847Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NA · 1 location(s) · Zhejiang Provincial People's Hospital · NCT07068542A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carc
Phase 3 · 35 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06860971Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Phase 3 · 301 location(s) · ECOG-ACRIN Cancer Research Group · NCT06475989Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT05789667Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT06898437Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Diff
Phase N/A · 3 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05994365Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06970353Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06007924
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.